Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic...

Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht...

Inotuzumab ozogamicin in paediatric CD22-positive r/r acute lymphoblastic leukaemia: results of the ITCC-059 study ( Dr Erica Brivio - Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands )

MURANO: Sustained disease survival in CLL following venetoclax plus rituximab

Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands

MURANO: Sustained disease survival in CLL following venetoclax plus rituximab ( Dr Arnon Kater - Cancer Center Amsterdam, Amsterdam, Netherlands )

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk...

Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA

Comparing outcomes of first-line ibrutinib vs chemoimmunotherapy in high-risk CLL ( Dr Lori Leslie - John Theurer Cancer Center, Hackensack, USA )

OncoAlert and ecancer weekly roundup for November 22 - Dec 5, 2020

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly roundup for November 22 - Dec 5, 2020 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the...

Dr Jorge Cortes - Augusta University, Augusta, USA

First-in-class STAMP inhibitor asciminib in patients with CML harbouring the T315I mutation ( Dr Jorge Cortes - Augusta University, Augusta, USA )

Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin...

Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia

$Analysis of the B-HOLISTIC study and importance of relapsed/refractory Hodgkin lymphoma real world evidence data ( Prof Mark Hertzberg - Prince of Wales Hospital, Sydney, Australia )$

Five year update of ECHELON-1 for classical Hodgkin lymphoma

Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil

Five year update of ECHELON-1 for classical Hodgkin lymphoma ( Dr Otavio Baiocchi - Centro Especializado em Oncologia, São Paulo, Brazil )

Real world management of multiple myeloma patients

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

Real world management of multiple myeloma patients ( Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina )

Evaluation of MRD negativity in patients with relapsed or refractory multiple...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

$Evaluation of MRD negativity in patients with relapsed or refractory multiple myeloma treated in the CANDOR study ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )$

Ponatinib, venetoclax and dexamethasone for patients with relapsed or...

Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA

$Ponatinib, venetoclax and dexamethasone for patients with relapsed or refractory Philadelphia chromosome-positive ALL ( Dr Nicholas Short - MD Anderson Cancer Center, Houston, USA )$

Predictive factors for overall survival in chronic myeloid leukaemia patients:...

Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy

Predictive factors for overall survival in chronic myeloid leukaemia patients: an analysis by the Gimema CML Italian study ( Prof Giuseppe Saglio - A.O. Ordine Mauriziano, Turin, Italy )

Cranial radiation mostly eliminated in children with T-ALL and bortezomib...

Prof David Teachey - The University of Pennsylvania, Rutledge, USA

Cranial radiation mostly eliminated in children with T-ALL and bortezomib potentially improves survival in children with T-LL ( Prof David Teachey - The University of Pennsylvania, Rutledge, USA )

More from ecancer